ARelaxin receptor agonist drug (RRA01)for theacute heart failuretreatment is developed by the Sunny Pharmaceutical Company. It is a publicly traded company. The reduction of cardiovascular death (mortality) was used as the end point (results of the research) for this investigation.The null hypothesis is "there is no difference in the cardiovascular mortality reduction between patients who received RRA01 (treatment group) and those who did not receive RRA01 (control group).Discuss the impact (on the company and/or on the patients) of the following two possible clinical trial results to the Sunny Pharmaceutical Company, staff of the company, and the patients. The tests were conducted at significancelevel of 0.05.

1. p = 0.002 as the hypothesis test results

2. p =0.3 as the hypothesis test results.